In silico simulation of inhibitor drug effects on nuclear factor-κB pathway dynamics

Molecular Pharmacology

Volumn 66, Issue 1, 2004, Pages 70-75

  Sung, Myong Hee ^a   Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME INHIBITOR; TRANSCRIPTION FACTOR;

APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CELL SURVIVAL; CLINICAL PROTOCOL; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; KINETICS; MATHEMATICAL MODEL; OSCILLATORY POTENTIAL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SIMULATION; TRANSCRIPTION INITIATION;

COMPUTER SIMULATION; HUMANS; I-KAPPA B KINASE; MODELS, BIOLOGICAL; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 3042668006     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.66.1.70     Document Type: Article

References (11)

1. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, and Elliott PJ (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59:2615-2622.
2. Darnell JE Jr (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740-749.
3. Garg A and Aggarwal BB (2002) Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 16:1053-1068.
4. Ghosh S and Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81-S96.
5. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, et al. (2002) NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 277:16639-16647.
6. Hoffmann A, Levchenko A, Scott ML, and Baltimore D (2002) The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science (Wash DC) 298:1241-1245.
7. Ni H, Ergin M, Huang Q, Qin JZ, Amin HM, Martinez RL, Saeed S, Barton K, and Alkan S (2001) Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis. Br J Haematol 115:279-286.
8. Orlowski RZ and Baldwin AS Jr (2002) NF-kappaB as a therapeutic target in cancer. Trends Mol Med 8:385-389.
9. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, et al. (2002) Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 20:4420-4427.
10. Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866.
11. Sarkar CA and Lauffenburger DA (2003) Cell-level pharmacokinetic model of granulocyte colony-stimulating factor: implications for ligand lifetime and potency in vivo. Mol Pharmacol 63:147-158.